Euclises Pharmaceuticals
Euclises Pharmaceuticals: Innovating in drug discovery and development for inflammation and oncology.
Founded
2011Euclises Pharmaceuticals: Innovating in drug discovery and development for inflammation and oncology.
Euclises Pharmaceuticals, founded with a mission to innovate in drug discovery and development, focuses on creating novel treatments for inflammation and oncology. The company's vision is to bring safe and effective therapies to patients suffering from cancer. Euclises specializes in developing Euclicoxibs®, a class of drugs designed to safely treat cancers by targeting COX enzymes, aiming to maximize anti-cancer efficacy while minimizing side effects.
Notable figures associated with Euclises Pharmaceuticals include experienced researchers and industry experts in the fields of inflammation and oncology. The company has garnered attention from key investors in the pharmaceutical sector, supporting its groundbreaking research. Euclises' significant achievements include advancing its proprietary Euclicoxibs® through various stages of clinical trials, demonstrating promising results in cancer treatment. The overall impact of Euclises Pharmaceuticals lies in its potential to revolutionize cancer therapy, offering new hope to patients worldwide.
Companies similar to Euclises Pharmaceuticals include Eolo Pharma, Onchilles Pharma, Innocrin Pharmaceuticals and CNBX Pharmaceuticals.
Euclises Pharmaceuticals was founded in 2011.
Euclises Pharmaceuticals' headquarters is located in St. Louis, MO, US.
Euclises Pharmaceuticals' most recent funding round was for $1.2M (USD) in December 2016.
As of Dec 1, 2016, Euclises Pharmaceuticals has disclosed funding of $5.4M (USD). Undisclosed round amounts are excluded.
Euclises Pharmaceuticals has 5 employees as of Feb 5, 2024.
CNBX Pharmaceuticals
cnbxpharma.com
